EGFR

Summary

Gene Symbol: EGFR
Description: epidermal growth factor receptor
Alias: ERBB, ERBB1, HER1, NISBD2, PIG61, mENA, avian erythroblastic leukemia viral (v-erb-b) oncogene homolog, cell growth inhibiting protein 40, cell proliferation-inducing protein 61, erb-b2 receptor tyrosine kinase 1, proto-oncogene c-ErbB-1, receptor tyrosine-protein kinase erbB-1
Species: human

Top Publications

  1. doi Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    Tony S Mok
    State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong
    N Engl J Med 361:947-57. 2009
  2. doi Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
    Makoto Maemondo
    Miyagi Cancer Center, Miyagi, Japan
    N Engl J Med 362:2380-8. 2010
  3. doi Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
    Rafael Rosell
    Catalan Institute of Oncology, Badalona, Spain
    Lancet Oncol 13:239-46. 2012
  4. doi Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
    Tetsuya Mitsudomi
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, Chikusa ku, Nagoya, Japan
    Lancet Oncol 11:121-8. 2010
  5. ncbi Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
    Thomas J Lynch
    Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston 02129, USA
    N Engl J Med 350:2129-39. 2004
  6. doi Screening for epidermal growth factor receptor mutations in lung cancer
    Rafael Rosell
    Catalan Institute of Oncology and Autonomous University of Barcelona, Hospital Germans Trias i Pujol, Barcelona, Spain
    N Engl J Med 361:958-67. 2009
  7. doi Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer
    Pierre Laurent-Puig
    INSERM UMR S775 Molecular Basis of Xenobiotics Response, Paris, France
    J Clin Oncol 27:5924-30. 2009
  8. pmc Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK
    Alice T Shaw
    Department of Pathology, Massachusetts General Hospital, Warren 501c, 55 Fruit St, Boston, MA 02114, USA
    J Clin Oncol 27:4247-53. 2009
  9. ncbi EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy
    J Guillermo Paez
    Departments of Medical Oncology and Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Science 304:1497-500. 2004
  10. ncbi EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
    Susumu Kobayashi
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA
    N Engl J Med 352:786-92. 2005

Detail Information

Publications375 found, 100 shown here

  1. doi Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    Tony S Mok
    State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong
    N Engl J Med 361:947-57. 2009
    ..Previous, uncontrolled studies have suggested that first-line treatment with gefitinib would be efficacious in selected patients with non-small-cell lung cancer...
  2. doi Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
    Makoto Maemondo
    Miyagi Cancer Center, Miyagi, Japan
    N Engl J Med 362:2380-8. 2010
    Non-small-cell lung cancer with sensitive mutations of the epidermal growth factor receptor (EGFR) is highly responsive to EGFR tyrosine kinase inhibitors such as gefitinib, but little is known about how its efficacy and safety profile ..
  3. doi Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
    Rafael Rosell
    Catalan Institute of Oncology, Badalona, Spain
    Lancet Oncol 13:239-46. 2012
    ..when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations...
  4. doi Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
    Tetsuya Mitsudomi
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, Chikusa ku, Nagoya, Japan
    Lancet Oncol 11:121-8. 2010
    Patients with non-small-cell lung cancer harbouring mutations in the epidermal growth factor receptor (EGFR) gene respond well to the EGFR-specific tyrosine kinase inhibitor gefitinib...
  5. ncbi Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
    Thomas J Lynch
    Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston 02129, USA
    N Engl J Med 350:2129-39. 2004
    ..have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR). However, about 10 percent of patients have a rapid and often dramatic clinical response...
  6. doi Screening for epidermal growth factor receptor mutations in lung cancer
    Rafael Rosell
    Catalan Institute of Oncology and Autonomous University of Barcelona, Hospital Germans Trias i Pujol, Barcelona, Spain
    N Engl J Med 361:958-67. 2009
    Activating mutations in the epidermal growth factor receptor gene (EGFR) confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with advanced non-small-cell lung cancer...
  7. doi Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer
    Pierre Laurent-Puig
    INSERM UMR S775 Molecular Basis of Xenobiotics Response, Paris, France
    J Clin Oncol 27:5924-30. 2009
    ..predictive of nonresponse and shorter survival in patients treated by anti-epidermal growth factor receptor (anti-EGFR) antibody for metastatic colorectal cancer (mCRC), leading the European Medicine Agency to limit its use to ..
  8. pmc Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK
    Alice T Shaw
    Department of Pathology, Massachusetts General Hospital, Warren 501c, 55 Fruit St, Boston, MA 02114, USA
    J Clin Oncol 27:4247-53. 2009
    ..To aid in identification and treatment of these patients, we examined the clinical characteristics and treatment outcomes of patients who had NSCLC with and without EML4-ALK...
  9. ncbi EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy
    J Guillermo Paez
    Departments of Medical Oncology and Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Science 304:1497-500. 2004
    ..Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15of 58 unselected tumors from Japan and 1 of 61 from the United States...
  10. ncbi EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
    Susumu Kobayashi
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA
    N Engl J Med 352:786-92. 2005
    Mutations of the epidermal growth factor receptor (EGFR) gene have been identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors...
  11. ncbi An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor
    Xuewu Zhang
    Department of Molecular and Cell Biology, Howard Hughes Medical Institute, University of California, Berkeley, 94720, USA
    Cell 125:1137-49. 2006
    The mechanism by which the epidermal growth factor receptor (EGFR) is activated upon dimerization has eluded definition...
  12. pmc Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
    Zhenfeng Zhang
    1 Department of Pathology, Case Western Reserve University School of Medicine, University Hospitals Case Medical Center and Ireland Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, USA
    Nat Genet 44:852-60. 2012
    Human non-small cell lung cancers (NSCLCs) with activating mutations in EGFR frequently respond to treatment with EGFR-targeted tyrosine kinase inhibitors (TKIs), such as erlotinib, but responses are not durable, as tumors acquire ..
  13. pmc EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib
    William Pao
    Program in Cancer Biology and Genetics and Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 101:13306-11. 2004
    Somatic mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene are reportedly associated with sensitivity of lung cancers to gefitinib (Iressa), kinase inhibitor...
  14. ncbi Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains
    Hideo Ogiso
    RIKEN Genomic Sciences Center, 1 7 22 Suehiro cho, Tsurumi, 230 0045, Yokohama, Kanagawa, Japan
    Cell 110:775-87. 2002
    Epidermal growth factor (EGF) regulates cell proliferation and differentiation by binding to the EGF receptor (EGFR) extracellular region, comprising domains I-IV, with the resultant dimerization of the receptor tyrosine kinase...
  15. ncbi c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function
    J S Biscardi
    Department of Microbiology and Cancer Center, Box 441, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA
    J Biol Chem 274:8335-43. 1999
    Accumulating evidence indicates that interactions between the epidermal growth factor receptor (EGFR) and the nonreceptor tyrosine kinase c-Src may contribute to an aggressive phenotype in multiple human tumors...
  16. doi Spatial control of EGF receptor activation by reversible dimerization on living cells
    Inhee Chung
    Genentech, Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nature 464:783-7. 2010
    Epidermal growth factor receptor (EGFR) is a type I receptor tyrosine kinase, the deregulation of which has been implicated in a variety of human carcinomas...
  17. ncbi Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1
    G Levkowitz
    Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel
    Mol Cell 4:1029-40. 1999
    ..that Cbl adaptor proteins directly control downregulation of the receptor for the epidermal growth factor (EGFR) by recruiting ubiquitin-activating and -conjugating enzymes...
  18. ncbi Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib
    David A Eberhard
    Department of Pathology, Genentech Inc, San Francisco, CA, USA
    J Clin Oncol 23:5900-9. 2005
    Epidermal growth factor receptor (EGFR) mutations have been associated with tumor response to treatment with single-agent EGFR inhibitors in patients with relapsed non-small-cell lung cancer (NSCLC)...
  19. pmc Multiple mechanisms collectively regulate clathrin-mediated endocytosis of the epidermal growth factor receptor
    Lai Kuan Goh
    Department of Pharmacology, School of Medicine, University of Colorado Denver, Aurora, CO 80045, USA
    J Cell Biol 189:871-83. 2010
    Endocytosis of the epidermal growth factor receptor (EGFR) is important for the regulation of EGFR signaling...
  20. pmc EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance
    Yongjie Wei
    Center for Autophagy Research, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    Cell 154:1269-84. 2013
    ..Here, we defined the molecular basis by which the epidermal growth factor receptor (EGFR) tyrosine kinase regulates autophagy...
  21. pmc The role of EGF receptor ubiquitination in regulating its intracellular traffic
    Emily R Eden
    UCL Institute of Ophthalmology, University College London, 11 43 Bath Street, London, EC1V 9EL, UK
    Traffic 13:329-37. 2012
    Progression of activated EGF receptor (EGFR) through the endocytic pathway regulates EGFR signaling...
  22. doi First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center, 32 Fruit St, Yawkey Suite 7B, Boston, MA 02114, USA
    J Clin Oncol 26:2442-9. 2008
    Somatic mutations in the epidermal growth factor receptor (EGFR) correlate with increased response in patients with non-small-cell lung cancer (NSCLC) treated with EGFR tyrosine kinase inhibitors (TKIs)...
  23. doi Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
    Yi long Wu
    Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China Electronic address
    Lancet Oncol 15:213-22. 2014
    Afatinib-an oral irreversible ErbB family blocker-improves progression-free survival compared with pemetrexed and cisplatin for first-line treatment of patients with EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC)...
  24. pmc An unbiased screen identifies DEP-1 tumor suppressor as a phosphatase controlling EGFR endocytosis
    Gabi Tarcic
    Department of Biological Regulation, The Weizmann Institute of Science, Rehovot 76100, Israel
    Curr Biol 19:1788-98. 2009
    The epidermal growth factor (EGF) stimulates rapid tyrosine phosphorylation of the EGF receptor (EGFR)...
  25. ncbi Crystal structure of the ubiquitin binding domains of rabex-5 reveals two modes of interaction with ubiquitin
    Lorenza Penengo
    IFOM, the FIRC Institute for Molecular Oncology Foundation, Via Adamello 16, 20139 Milan, Italy
    Cell 124:1183-95. 2006
    ..The two binding surfaces allow Ub to interact simultaneously with different UBDs, thus opening new perspectives in Ub-mediated signaling...
  26. ncbi KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer
    Erminia Massarelli
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Clin Cancer Res 13:2890-6. 2007
    b>EGFR gene mutations and increased EGFR copy number have been associated with favorable response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKI) in patients with non-small-cell lung cancer (NSCLC)...
  27. pmc LIV-1 promotes prostate cancer epithelial-to-mesenchymal transition and metastasis through HB-EGF shedding and EGFR-mediated ERK signaling
    Hui Wen Lue
    Department of Biology, Georgia State University, Atlanta, Georgia, United States of America
    PLoS ONE 6:e27720. 2011
    ..growth factor (HB-EGF) from ARCaP(E) cells that elicited constitutive epidermal growth factor receptor (EGFR) phosphorylation and its downstream extracellular signal regulated kinase (ERK) signaling...
  28. doi β1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells
    V Morello
    Molecular Biotechnology Center, University of Torino, Italy
    Oncogene 30:4087-96. 2011
    Lung cancer is the leading cause of cancer death worldwide. The epidermal growth factor receptor (EGFR) represents the main target for non-small cell lung cancer (NSCLC) therapy, as its overexpression or constitutive activation ..
  29. ncbi Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting
    John C Sok
    Department of Otolaryngology, and University of Pittsburgh Cancer Institute Biostatistics, University of Pittsburgh, Pennsylvania 15213, USA
    Clin Cancer Res 12:5064-73. 2006
    Epidermal growth factor receptor (EGFR) is overexpressed in head and neck squamous cell carcinoma (HNSCC) where expression levels correlate with decreased survival...
  30. doi Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer
    Hua Bai
    Peking University Cancer Hospital and Institute, Beijing, China
    J Clin Oncol 30:3077-83. 2012
    b>EGFR mutation is a predictor of epidermal growth factor receptor-tyrosine kinase inhibitor treatment response in patients with non-small-cell lung cancer (NSCLC)...
  31. ncbi Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation
    Kaisa Haglund
    Ludwig Institute for Cancer Research, Husargatan 3, SE 75 124 Uppsala, Sweden
    Nat Cell Biol 5:461-6. 2003
    ..Thus, monoubiquitination is the principal signal responsible for the movement of RTKs from the plasma membrane to the lysosome...
  32. doi Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response
    Jenn Yu Wu
    Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    Clin Cancer Res 14:4877-82. 2008
    ..in patients of non-small cell lung cancer (NSCLC) with mutations in exon 20 of epidermal growth factor receptor (EGFR) are limited...
  33. doi Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene
    Tsuyoshi Takahashi
    Department of Thoracic Surgery, Faculty of Medicine, Kyoto University, Kyoto, Japan
    Ann Surg Oncol 17:889-97. 2010
    ..We screened for EML4-ALK fusion genes and examined the clinicopathological and genetic characteristics of fusion-harboring NSCLC tumors...
  34. ncbi Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
    Hisayuki Shigematsu
    Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX 75390 8593, USA
    J Natl Cancer Inst 97:339-46. 2005
    Mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene in lung cancers are associated with increased sensitivity of these cancers to drugs that inhibit EGFR kinase activity...
  35. ncbi PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib
    Jeffrey A Engelman
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
    Cancer Res 67:11924-32. 2007
    Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors gefitinib and erlotinib are effective treatments for a subset of non-small cell lung cancers...
  36. doi Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation
    Sara Sigismund
    IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy
    Dev Cell 15:209-19. 2008
    Clathrin-mediated endocytosis (CME) is the major pathway of epidermal growth factor receptor (EGFR) internalization...
  37. pmc An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors
    D Chitale
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Oncogene 28:2773-83. 2009
    ..This showed non-random patterns of copy number alterations significantly linked to EGFR and KRAS mutation status and to distinct clinical outcomes, and led to the discovery of a striking association of ..
  38. pmc Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment
    Natalia Jura
    Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA
    Cell 137:1293-307. 2009
    ..The formation of the activating juxtamembrane latch is prevented by the C-terminal tails in a structure of an inactive kinase domain dimer, suggesting how alternative dimers can prevent ligand-independent activation...
  39. pmc Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas
    Sizhi Paul Gao
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Clin Invest 117:3846-56. 2007
    ..in primary adenocarcinomas and cell lines harboring somatic-activating mutations in the tyrosine kinase domain of EGFR. Treatment of cell lines with either an EGFR inhibitor or an src kinase inhibitor had no effect on pSTAT3 levels, ..
  40. doi EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF
    Yu Ting Chou
    Institute of Biomedical Sciences and NRPGM Core Facilities for Proteomics and Glycomcis and Institute of Biological Chemistry, Academia Sinica, Taipei, Taiwan
    Cancer Res 70:8822-31. 2010
    MicroRNAs (miRNA) mediate distinct gene regulatory pathways triggered by epidermal growth factor receptor (EGFR) activation, which occurs commonly in lung cancers with poor prognosis...
  41. doi Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach
    Manuel Salto-Tellez
    Department of Pathology, National University Health System, Cancer Science Institute of Singapore, National University of Singapore, Singapore
    J Thorac Oncol 6:1663-9. 2011
    ..confirmed the superior response rate and progression-free survival of using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor as first-line therapy compared with chemotherapy in patients with activating EGFR ..
  42. doi The epidermal growth factor receptor-L861Q mutation increases kinase activity without leading to enhanced sensitivity toward epidermal growth factor receptor kinase inhibitors
    Rama Krishna Kancha
    Department of Internal Medicine III, Technical University of Munich, Munich, Germany
    J Thorac Oncol 6:387-92. 2011
    Mutations in the epidermal growth factor receptor (EGFR) kinase domain such as EGFR-L858R and EGFR-G719S have been reported to activate the kinase and also sensitize a subset of patients with non-small cell lung cancer to EGFR kinase ..
  43. ncbi The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling
    E J Lowenstein
    Department of Pharmacology, New York University Medical Center, New York 10016
    Cell 70:431-42. 1992
    ..elegans protein sem-5. It has been shown that sem-5 and two other genes called let-23 (EGFR like) and let-60 (ras like) lie along the same signal transduction pathway controlling C. elegans vulval induction...
  44. ncbi Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase
    Klaus Dittmann
    Division of Radiobiology and Molecular Environmental Research, Department of Radiation Oncology, University of Tubingen, 72076 Tubingen, Germany
    J Biol Chem 280:31182-9. 2005
    Ionizing radiation, but not stimulation with epidermal growth factor (EGF), triggers EGF receptor (EGFR) import into the nucleus in a probably karyopherin alpha-linked manner...
  45. pmc Pathobiological implications of the expression of EGFR, pAkt, NF-κB and MIC-1 in prostate cancer stem cells and their progenies
    Murielle Mimeault
    Department of Biochemistry and Molecular Biology, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, United States of America
    PLoS ONE 7:e31919. 2012
    ..the possibility of using a combination of specific oncogenic products, including epidermal growth factor receptor (EGFR), pAkt, nuclear factor-kappaB (NF-κB) and macrophage inhibitory cytokine-1 (MIC-1) as biomarkers and therapeutic ..
  46. ncbi Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer
    Michio Inukai
    Department of Cancer and Thoracic Surgery, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama, Japan
    Cancer Res 66:7854-8. 2006
    The threonine-to-methionine substitution at amino acid position 790 (T790M) of the epidermal growth factor receptor (EGFR) gene has been reported in progressing lesions after gefitinib treatment in non-small cell lung cancer (NSCLC) that ..
  47. pmc Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer
    Kirstine Roepstorff
    Department of Cellular and Molecular Medicine, The Panum Institute, University of Copenhagen, Blegdamsvej 3, 2200 Copenhagen N, Denmark
    Histochem Cell Biol 129:563-78. 2008
    ErbB receptors (EGFR (ErbB1), ErbB2, ErbB3, and ErbB4) are important regulators of normal growth and differentiation, and they are involved in the pathogenesis of cancer...
  48. pmc Use of immunohistochemical markers can refine prognosis in triple negative breast cancer
    Marc Tischkowitz
    Program in Cancer Genetics, McGill University, Montreal, Quebec, Canada
    BMC Cancer 7:134. 2007
    ..The IHC pattern that best defines basal-like tumors is under investigation and various combinations of ER, PR, HER2-, CK5/6+ and EGFR+ have been tested.
  49. doi Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer
    Sarah Park
    Department of Medicine, Division of Hematology Oncology, Hangang Sacred Heart Hospital, Hallym University School of Medicine, Seoul, Korea
    J Thorac Oncol 4:809-15. 2009
    For the identification of the patients who most likely benefit from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC), molecular assays are considered to be of paramount importance...
  50. doi NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma
    Tomoya Yamaguchi
    Division of Molecular Carcinogenesis, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Showa Ku, Nagoya 466 8550, Japan
    Cancer Cell 21:348-61. 2012
    ..in part through ROR1 kinase-dependent c-Src activation, as well as kinase activity-independent sustainment of the EGFR-ERBB3 association, ERBB3 phosphorylation, and consequential PI3K activation...
  51. pmc MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
    James Bean
    Human Oncology and Pathogenesis Program, Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 104:20932-7. 2007
    In human lung adenocarcinomas harboring EGFR mutations, a second-site point mutation that substitutes methionine for threonine at position 790 (T790M) is associated with approximately half of cases of acquired resistance to the EGFR ..
  52. doi Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer
    Tetsuya Mitsudomi
    Department of Thoracic Surgery, Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan
    FEBS J 277:301-8. 2010
    Epidermal growth factor receptor (EGFR) and its three related proteins (the ERBB family) are receptor tyrosine kinases that play essential roles in both normal physiological conditions and cancerous conditions...
  53. ncbi Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway
    Hui Wen Lo
    Cancer Cell 7:575-89. 2005
    Epidermal growth factor receptor (EGFR) exists in the nucleus of highly proliferative cells where it functions as a transcription factor...
  54. pmc Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)
    K Tamura
    Outpatients Treatment Center, National Cancer Center Hospital, 5 1 1, Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Br J Cancer 98:907-14. 2008
    ..was to evaluate the efficacy of gefitinib and the feasibility of screening for epidermal growth factor receptor (EGFR) mutations among select patients with advanced non-small cell lung cancer (NSCLC)...
  55. doi Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop
    Robert Pirker
    Medical University of Vienna, Vienna, Austria
    J Thorac Oncol 5:1706-13. 2010
    Activating somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor (EGFR) have recently been characterized in a subset of patients with advanced non-small cell lung cancer (NSCLC)...
  56. pmc Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma
    James Bean
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 14:7519-25. 2008
    Somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene are associated with sensitivity of lung adenocarcinomas to the EGFR tyrosine kinase inhibitors, gefitinib and erlotinib...
  57. doi Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy
    Chih Hsin Yang
    Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
    J Clin Oncol 26:2745-53. 2008
    ..To explore predictive factors for time to treatment failure (TTF) in chemotherapy-naive non-small-cell lung cancer (NSCLC) patients receiving gefitinib treatment...
  58. pmc Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation
    Geoffrey R Oxnard
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York 10065, USA
    Clin Cancer Res 17:1616-22. 2011
    Patients with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI) after a median of 10 to 16 months...
  59. pmc BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
    D Li
    Department of Medical Oncology, Dana Farber Cancer Institute, MA, USA
    Oncogene 27:4702-11. 2008
    Genetic alterations in the kinase domain of the epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) patients are associated with sensitivity to treatment with small molecule tyrosine kinase inhibitors...
  60. doi Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer
    B Corkery
    National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin
    Ann Oncol 20:862-7. 2009
    ..Epidermal growth factor receptor (EGFR) is frequently overexpressed in TNBC...
  61. doi Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples
    Audrey Didelot
    UMR S775, INSERM, Paris, F 75006, France
    Exp Mol Pathol 92:275-80. 2012
    ..The development of targeted therapies has created a need for robust molecular characterization of cancer and it has become a challenge to validate methods to ensure accuracy in tumor mutation testing...
  62. pmc EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway
    R Bonavia
    Ludwig Institute for Cancer Research, University of California, La Jolla, CA, USA
    Oncogene 31:4054-66. 2012
    ..Here, we show that expression of the constitutively active mutant epidermal growth factor receptor, ΔEGFR (EGFRvIII, EGFR*, de2-7EGFR) is associated with significantly higher expression levels of the pro-angiogenic factor ..
  63. pmc Cyclooxygenase-2 is a novel transcriptional target of the nuclear EGFR-STAT3 and EGFRvIII-STAT3 signaling axes
    Hui Wen Lo
    Department of Surgery, Duke University, 433A MSRB I, 103 Research Drive, Durham, NC 27710, USA
    Mol Cancer Res 8:232-45. 2010
    Emerging evidence indicates a novel mode of epidermal growth factor receptor (EGFR) signaling, notably, one involves EGFR nuclear translocalization and subsequent gene activation...
  64. pmc Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity
    Yuan Rong
    Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
    Cancer Res 69:2540-9. 2009
    ..Epidermal growth factor receptor (EGFR) amplification and PTEN loss are two common genetic alterations seen in GBM but not in lower-grade astrocytomas ..
  65. doi Epithelial-mesenchymal-transition induced by EGFR activation interferes with cell migration and response to irradiation and cetuximab in head and neck cancer cells
    Carmen Holz
    Laboratory for Translational Radiobiology and Radiooncology, Department of Radiooncology, Charite Campus Mitte, Berlin, Germany
    Radiother Oncol 101:158-64. 2011
    The role of epithelial-mesenchymal transition (EMT) in the poor outcome of EGFR-overexpressing SCCHN was evaluated.
  66. ncbi High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan
    Shiu Feng Huang
    Division of Molecular and Genomic Medicine, National Health Research Institutes, Taipei, Taiwan
    Clin Cancer Res 10:8195-203. 2004
    Epidermal growth factor receptor (EGFR) mutations related to gefitinib responsiveness in non-small cell lung cancer have been found recently...
  67. doi Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer
    Jian Yu
    Cell Signaling Technology, Inc, Danvers, Massachusetts, USA
    Clin Cancer Res 15:3023-8. 2009
    Activating mutations within the tyrosine kinase domain of epidermal growth factor receptor (EGFR) are found in approximately 10% to 20% of non-small-cell lung cancer (NSCLC) patients and are associated with response to EGFR inhibitors...
  68. ncbi EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus
    Mitsuhiko Hanawa
    Department of Pathology, School of Medicine, University of Yamanashi, Japan
    Int J Cancer 118:1173-80. 2006
    Overexpression of epidermal growth factor receptor (EGFR) is observed in many cancers, sometimes accompanied by gene amplification...
  69. ncbi Assessment of epidermal growth factor receptor mutation by endobronchial ultrasound-guided transbronchial needle aspiration
    Takahiro Nakajima
    Department of Thoracic Surgery, Graduate School of Medicine, Chiba University, 1 8 1 Inohana, Chuo Ku, Chiba 260 8670, Japan
    Chest 132:597-602. 2007
    The presence of somatic mutations in epidermal growth factor receptor (EGFR) predicts the effectiveness of EGFR tyrosine kinase inhibitors (TKIs)...
  70. pmc Induction of epidermal growth factor receptor expression by Epstein-Barr virus latent membrane protein 1 C-terminal-activating region 1 is mediated by NF-kappaB p50 homodimer/Bcl-3 complexes
    Natalie J Thornburg
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    J Virol 81:12954-61. 2007
    ..CTAR1 also uniquely upregulates the epidermal growth factor receptor (EGFR). In NPC, NF-kappaB p50/p50 homodimers and the transactivator Bcl-3 were detected on the EGFR promoter...
  71. doi A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells
    Miguel A Molina-Vila
    Catalan Institute of Oncology, Medical Oncology Service, Hosptial Germans Trias i Pujol, Badalona, Spain
    J Thorac Oncol 3:1224-35. 2008
    Detection of epidermal growth factor receptor (EGFR) mutations in advanced non-small cell lung cancer (NSCLC) patients has relied on DNA purification from biopsies, amplification, and sequencing...
  72. doi A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases
    Sara E Monaco
    Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA 15232, USA
    Hum Pathol 41:94-102. 2010
    Epidermal growth factor receptor (EGFR) and v-Ki-ras 2 (KRAS; viral Kirsten rat sacoma 2 oncogene homolog) oncogenes are predictors of response to EGFR-targeted therapy in lung carcinomas...
  73. ncbi Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib
    Floriana Morgillo
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 66:10100-11. 2006
    Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been used to treat non-small cell lung cancer (NSCLC)...
  74. ncbi Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib
    Gregory J Riely
    Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 12:839-44. 2006
    In patients with non-small cell lung cancer (NSCLC), mutations in the epidermal growth factor receptor (EGFR) tyrosine kinase domain have been associated with sensitivity to erlotinib and gefitinib...
  75. doi Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial
    Jean Yves Douillard
    M D Anderson Cancer Center, Thoracic Head and Neck Medical Oncology, Box 432, 1515 Holcombe Blvd, Houston, TX 77401, USA
    J Clin Oncol 28:744-52. 2010
    ..METHODS Biomarkers included epidermal growth factor receptor (EGFR) copy number by fluorescent in situ hybridization (374 assessable samples), EGFR protein expression by ..
  76. pmc Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients
    Kan V Lu
    Department of Pathology and Laboratory Medicine, University of California Los Angeles David Geffen School of Medicine, USA
    Cancer Res 69:6889-98. 2009
    Activating epidermal growth factor receptor (EGFR) mutations are common in many cancers including glioblastoma. However, clinical responses to EGFR inhibitors are infrequent and short-lived...
  77. doi Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer
    Hua Bai
    Department of Thoracic Medical Oncology Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing, China
    J Clin Oncol 27:2653-9. 2009
    Mutations in the epidermal growth factor receptor (EGFR) kinase domain can predict tumor response to tyrosine kinase inhibitors (TKIs) in non-small-cell lung cancer (NSCLC)...
  78. pmc Desmoglein 1-dependent suppression of EGFR signaling promotes epidermal differentiation and morphogenesis
    Spiro Getsios
    Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    J Cell Biol 185:1243-58. 2009
    ..In addition to serving as a rigid anchor between adjacent cells, this study implicates desmosomal cadherins as key components of a signaling axis governing epithelial morphogenesis...
  79. pmc A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling
    Hadassa Waterman
    Department of Biological Regulation, The Weizmann Institute of Science, Rehovot 76100, Israel
    EMBO J 21:303-13. 2002
    Ligand-induced desensitization of the epidermal growth factor receptor (EGFR) is controlled by c-Cbl, a ubiquitin ligase that binds multiple signaling proteins, including the Grb2 adaptor...
  80. pmc FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR
    Trever G Bivona
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, New York 10065, USA
    Nature 471:523-6. 2011
    Human lung adenocarcinomas with activating mutations in EGFR (epidermal growth factor receptor) often respond to treatment with EGFR tyrosine kinase inhibitors (TKIs), but the magnitude of tumour regression is variable and transient...
  81. pmc Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice
    Leina Sun
    Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, China
    J Exp Clin Cancer Res 30:30. 2011
    Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) have been widely used for the treatment of non-small cell lung cancer (NSCLC)...
  82. pmc Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis
    Yang Zhang
    Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, 270 Dong An Road, Shanghai 200032, China
    Clin Cancer Res 18:1947-53. 2012
    ..96] of Chinese never-smokers with lung adenocarcinoma harbor known oncogenic driver mutations in just four genes EGFR, ALK, HER2, and KRAS...
  83. pmc High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer
    Jennifer L Clarke
    Department of Neurology and Brain Tumor Center, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    J Neurooncol 99:283-6. 2010
    ..We describe LM from lung adenocarcinoma harboring a mutation in the epidermal growth factor receptor (EGFR) gene that confers sensitivity to the EGFR tyrosine kinase inhibitors (EGFR-TKIs) erlotinib and gefitinib...
  84. ncbi Regulation of ubiquitin protein ligase activity in c-Cbl by phosphorylation-induced conformational change and constitutive activation by tyrosine to glutamate point mutations
    C Kenneth Kassenbrock
    Department of Pathology, University of Colorado Health Sciences Center, 4200 E Ninth Avenue, Denver, CO 80262, USA
    J Biol Chem 279:28017-27. 2004
    ..a Y371E mutant shows constitutive E3 activity while retaining the ability to bind epidermal growth factor receptor (EGFR)...
  85. pmc A Fra-1-dependent, matrix metalloproteinase driven EGFR activation promotes human lung epithelial cell motility and invasion
    Pavan Adiseshaiah
    Department of Environmental Health Sciences, Bloomberg School of Public Health, Baltimore, Maryland, USA
    J Cell Physiol 216:405-12. 2008
    ..Furthermore, Fra-1 induced EGFR phosphorylation in an MMP-dependent manner, and an EGFR-specific inhibitor was able to block Fra-1-enhanced cell ..
  86. doi Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center and Dana Farber Cancer Center, Harvard Medical School, Boston, MA 02114, USA
    J Clin Oncol 28:3076-83. 2010
    Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have had a significant impact on non-small-cell lung cancer (NSCLC) outcomes, particularly for patients with EGFR mutations...
  87. pmc Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer
    Caterina Peraldo-Neia
    Department of Clinical Oncology, University of Torino Medical School, Institute for Cancer Research and Treatment, Candiolo, Turin, Italy
    BMC Cancer 11:31. 2011
    Activating mutations of the epidermal growth factor receptor (EGFR) confer sensitivity to the tyrosine kinase inhibitors (TKi), gefitinib and erlotinib...
  88. pmc HECT E3 ubiquitin ligase Nedd4-1 ubiquitinates ACK and regulates epidermal growth factor (EGF)-induced degradation of EGF receptor and ACK
    Qiong Lin
    Weis Center for Research, Geisinger Clinic, Danville, Pennsylvania 17822, USA
    Mol Cell Biol 30:1541-54. 2010
    ..an important role in ligand-induced and ubiquitination-mediated degradation of epidermal growth factor receptor (EGFR)...
  89. pmc Phosphorylation of Y845 on the epidermal growth factor receptor mediates binding to the mitochondrial protein cytochrome c oxidase subunit II
    Julie L Boerner
    Department of Microbiology and Cancer Center, University of Virginia Health System, Charlottesville, VA 22908, USA
    Mol Cell Biol 24:7059-71. 2004
    When co-overexpressed, the epidermal growth factor receptor (EGFR) and c-Src cooperate to cause synergistic increases in EGF-induced DNA synthesis, soft agar colony growth, and tumor formation in nude mice...
  90. ncbi Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis
    Fred R Hirsch
    Department of Pathology, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    J Clin Oncol 21:3798-807. 2003
    The epidermal growth factor receptor (EGFR) is frequently overexpressed in non-small-cell lung carcinoma (NSCLC), and EGFR inhibitors are promising new therapeutic agents...
  91. doi Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity
    Giuseppe Viale
    Division of Pathology, European Institute of Oncology, Milan, Italy
    Breast Cancer Res Treat 116:317-28. 2009
    ..significant worse disease-free and overall survival were observed in multivariate analysis, for patients with EGFR immunoreactivity in >or=50% invasive tumor cells (HR 2.39, 95% CI, 1.32-4.34, P = 0.004 for DFS; HR 2...
  92. pmc Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC
    A Kalikaki
    Laboratory of Tumor Cell Biology, School of Medicine, University of Crete, Heraklion, Crete, Greece
    Br J Cancer 99:923-9. 2008
    In non-small-cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR) and K-RAS mutations of the primary tumour are associated with responsiveness and resistance to tyrosine kinase inhibitors (TKIs), respectively...
  93. ncbi Binding of zinc finger protein ZPR1 to the epidermal growth factor receptor
    Z Galcheva-Gargova
    Department of Biochemistry and Molecular Biology, University of Massachusetts Medical School, Worcester, 01605, USA
    Science 272:1797-802. 1996
    ..a zinc finger protein that binds to the cytoplasmic tyrosine kinase domain of the epidermal growth factor receptor (EGFR)...
  94. doi The miR-200 family regulates the epithelial-mesenchymal transition induced by EGF/EGFR in anaplastic thyroid cancer cells
    Zhe Zhang
    Department of Integrated Therapy, Fudan University Shanghai Cancer Center, and Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, PR China
    Int J Mol Med 30:856-62. 2012
    ..The epidermal growth factor receptor (EGFR) is overexpressed in the majority of anaplastic thyroid cancers (ATCs)...
  95. ncbi Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
    Shiqing Li
    Department of Physiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Cancer Cell 7:301-11. 2005
    Recent structural studies of epidermal growth factor receptor (EGFR) family extracellular regions have identified an unexpected mechanism for ligand-induced receptor dimerization that has important implications for activation and ..
  96. ncbi Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib
    David M Jackman
    Lowe Center of Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 12:3908-14. 2006
    Somatic mutations in the epidermal growth factor receptor (EGFR) have been detected in patients with non-small cell lung cancer (NSCLC) and are associated with sensitivity to treatment with gefitinib or erlotinib...
  97. ncbi Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer
    Giuseppe Di Lorenzo
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi di Napoli Federico II, 80131 Naples, Italy
    Clin Cancer Res 8:3438-44. 2002
    The transforming growth factor alpha-epidermal growth factor receptor (EGFR) autocrine pathway has been implicated in prostate cancer cell growth...
  98. doi A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy
    Si Tuen Lee-Hoeflich
    Department of Pathology, Genentech, Inc, South San Francisco, CA 94080, USA
    Cancer Res 68:5878-87. 2008
    Epidermal growth factor receptor (EGFR) and HER3 each form heterodimers with HER2 and have independently been implicated as key coreceptors that drive HER2-amplified breast cancer...
  99. pmc Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR
    X Li
    Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Oncogene 31:4372-83. 2012
    Epidermal growth factor receptor (EGFR)-mediated cell signaling is critical for mammary epithelial cell growth and survival; however, targeting EGFR has shown no or only minimal therapeutic benefit in patients with breast cancer...
  100. pmc Internalization mechanisms of the epidermal growth factor receptor after activation with different ligands
    Lasse Henriksen
    Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark
    PLoS ONE 8:e58148. 2013
    The epidermal growth factor receptor (EGFR) regulates normal growth and differentiation, but dysregulation of the receptor or one of the EGFR ligands is involved in the pathogenesis of many cancers...
  101. ncbi The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer
    Shuji Ichihara
    Department of Cancer and Thoracic Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2 5 1 Shikata cho, Okayama 700 8558, Japan
    Int J Cancer 120:1239-47. 2007
    ..patients who had been treated with gefitinib, were screened for mutations in epidermal growth factor receptor (EGFR) exons 18-21, KRAS exon2, and polymorphisms including the CA simple sequence repeat in intron1 (CA-SSR1) and single ..

Research Grants120 found, 100 shown here

  1. Coexpression of EGFRvlll/ErbB2 in Human Breast Cancer
    Careen Tang; Fiscal Year: 2005
    ..86 percent (43/50) of ErbB-2 positive primary breast tumors were co-expressed with EGFRvIII...
  2. c-Src/EGF Receptors Interactions and Therapeutic Resistance in Breast Cancer
    Sarah J Parsons; Fiscal Year: 2010
    ..cancer patients the utilization of a novel signaling pathway emanating from the epidermal growth factor receptor (EGFR) that mediates resistance to drug therapy and to identify the downstream targets of this pathway...
  3. Theranostic Nanomedicine for Breast Cancer Prevention and Image-Guided Therapy
    Prakash R Rai; Fiscal Year: 2011
    ..vascular endothelial growth factor (VEGF), to membrane bound receptors, epidermal growth factor receptors (EGFR and HER2), their intracellular counterparts (intracellular VEGF ,EGFR and HER2), and the sub-nuclear protein PARP...
  4. Theranostic Nanomedicine for Breast Cancer Prevention and Image-Guided Therapy
    Prakash R Rai; Fiscal Year: 2013
    ..vascular endothelial growth factor (VEGF), to membrane bound receptors, epidermal growth factor receptors (EGFR and HER2), their intracellular counterparts (intracellular VEGF ,EGFR and HER2), and the sub-nuclear protein PARP...
  5. Alcohol and Breast Cancer
    Jia Luo; Fiscal Year: 2012
    ..Understanding the interactions among alcohol, ErbB2 and MUC1 will also provide an important insight into the pathogenesis of some human diseases related to alcohol abuse as well as alcohol's teratogenic effect during development. ..
  6. Protein-DNA Drug Carriers for Tumor Targeting
    Lali K Medina-Kauwe; Fiscal Year: 2012
    ..As HER2+ breast cancer does not respond well to conventional therapies, this alternative therapy could provide a significant contribution to breast cancer treatment, and could be modified to target therapy to other types of cancer. ..
  7. Exploiting synthetic-lethal interactions to target triple-negative breast cancers
    Dai Horiuchi; Fiscal Year: 2013
    ..If successful, the proposed research will not only expand our knowledge on MYC biology but will also provide novel therapeutic concepts to be tested again patients with TN tumors. ..
  8. Diagnostic Cancer Imaging using NIR Fluorescent Agents and FDPM
    Eva Sevick Muraca; Fiscal Year: 2009
    ..If successful, this project will provide the first clinical demonstration of fluorescence enhanced optical imaging in human patients with molecularly targeting NIR excitable contrast agents. ..
  9. Nuclear EGFR Signaling Network in Human Cancer
    Hui Wen Lo; Fiscal Year: 2010
    Epidermal growth factor receptor (EGFR) is critically involved in the genesis and progression of human cancers and is considered as an attractive target for anti-cancer therapy...
  10. Aptamer-siRNA Chimeras Targeting HER2-Positive Breast Cancers
    PALOMA HOBAN GIANGRANDE; Fiscal Year: 2013
    ..The successful completion of this work is expected to provide clinicians as well as breast cancer patients, including patients with refractory disease, with improved treatment choices for fighting HER2-positive cancers of the breast. ..
  11. Novel Mechanisms of EGFR Gene Expression Regulation
    Marianela Perez Torres; Fiscal Year: 2010
    ..the effects of neuregulins (NRGs) on the regulation of expression of the epidermal growth factor receptor (EGFR) and its soluble isoform p110 sEGFR...
  12. ASTATINE AND IODINE RADIOLABELED MONOCLONAL ANTIBODIES
    Michael Rod Zalutsky; Fiscal Year: 2013
    ..conduct all the toxicity, efficacy, dosimetry, and other FDA-required studies for Investigational New Drug permits, to all performance of clinical trials in malignant glioma patients under our Brain Tumor Center grant (NS20023 ..
  13. EXTENSION OF RADIOTHERAPY RESEARCH
    Raymond E Meyn; Fiscal Year: 2013
    ..Studies conducted through this project identified the epidermal growth factor receptor (EGFR) as an important determinant of cellular radiation sensitivity, elucidated mechanisms by which EGFR governs ..
  14. HDGF: a novel biomarker and therapetic target of lung cancer
    Li Mao; Fiscal Year: 2012
    ..in cancer progression, has shown encouraging results, such as the development of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and vascular endothelial growth factor (VEGF) inhibitors for patients with lung cancer...
  15. Determinants of Tumor Sensitivity to EGFR-Targeted Antibodies
    Louis M Weiner; Fiscal Year: 2013
    Determinants of tumor sensitivity to EGFR-targeted antibodies This project has focused on understanding the critical structural determinants of anti-tumor antibodies that promote tumor-specific, antibody-dependent cellular cytotoxicity (..
  16. EGFR Mutations in non-Small Cell Lung Cancer
    Bruce E Johnson; Fiscal Year: 2013
    ..The association between somatic mutations in the epidermal growth factor receptor (EGFR) and the clinical efficacy of the EGFR tyrosine kinase inhibitors, gefitinib and erlotinib, was discovered in 2004...
  17. Optimizing EGFR Targeted Therapy in Malignant Glioma
    Theodore Nicolaides; Fiscal Year: 2013
    ..The Epidermal Growth Factor Receptor (EGFR) features prominently in this disease, through over-expression, amplification and mutation...
  18. Role of Activated EGFR and COX-2 in Metastasis and Escape from Tumor Dormancy
    ANDREW GREGORY SIKORA; Fiscal Year: 2012
    ..experiments, supplemented by genetic analyses, suggest an important role for both epidermal growth factor receptor (EGFR) activation and cyclooygeanase-2 (COX-2) overexpression in HSNC metastasis...
  19. Xenoestrogen regulation of Leydig cells
    BENSON TOKUNBO AKINGBEMI; Fiscal Year: 2010
    ..protein Akt (protein kinase B) acting in concert with estrogen receptor ER1, epidermal growth factor receptors (EGFR), insulin growth factor-1 receptors (IGF-1R) and mitogen activated protein kinases (MAPK) (Aim II);and, Action of ..
  20. Phosphotyrosine signaling pathways controlling tracheal tube geometry
    KAI G ZINN; Fiscal Year: 2013
    ..of negative regulation by the RPTPs of three growth factor receptor TK orthologs: epidermal growth factor receptor (Egfr), Btl, and Pvr (VEGFR ortholog)...
  21. Regulation of PTHrP in Squamous Cell Carcinoma by the EGF Receptor
    GWENDOLEN LORCH; Fiscal Year: 2010
    ..Her research goal is to investigate epidermal growth factor receptor (EGFR) kinase signaling that leads to perturbed signal transduction and increased parathyroid hormone-related protein (..
  22. Regulation of Human Papillomavirus Replication via Cell Signaling Pathways
    ANASTACIA GRIEGO; Fiscal Year: 2013
    ..Early proteins E5, E6, And E7 from oncogenic HPV types are known to regulate epidermal growth factor receptor (EGFR) gene transcription and recycling in infected cells...
  23. Evaluating Novel Multi-kinase Peptide Inhibitors as a Treatment for Rheumatoid Ar
    DAVID MEN HWEI TSAI; Fiscal Year: 2013
    ..a novel milk peptide mixture (AX-3) that inhibits the tyrosine kinase activity of epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor 2 (VEGFR2), and insulin receptor (IR)...
  24. Zot, Zonulin, and Pathophysiology of Intestinal Tight Junctions
    Alessio Fasano; Fiscal Year: 2013
    ..both induce proteinase-activated receptor 2 (PAR2)-mediated transactivation of epidermal growth factor receptor (EGFR)...
  25. Regulation of Fibronectin Matrix Assembly by uPAR
    PAULA J MC KEOWN-LONGO; Fiscal Year: 2012
    ..uPAR ligation results in a Src-dependent transactivation of the epidermal growth factor receptor (EGFR) which results in the formation of EGFR/1521 integrin complexes, integrin activation and increased fibronectin ..
  26. REGULATION OF CXC CHEMOKINE EXPRESSION BY H. PYLORI
    Yoshio Yamaoka; Fiscal Year: 2013
    ..We will focus on the cell surface receptors epidermal growth factor receptor (EGFR) and G protein coupled receptor (GPCR)...
  27. Experimental COPD: remediation, mitigation
    DONALD JOHN MASSARO; Fiscal Year: 2010
    ..There is not treatment that slows the relentless progression of the disease or that reverses it. In this application, we use an animal model to investigate methods to slow progression and reverse the disease. ..
  28. microRNAs as novel biomarkers for management of breast cancer
    LORENZO SEMPERE; Fiscal Year: 2012
    ..Our results should provide a solid foundation to develop miRNA-based clinical assays to assist physicians in making crucial decisions with regards to treatment of patients. ..
  29. Mechanisms of Coronary Arteriolar Dysfunction in Type 2 Diabetes
    Khalid Matrougui; Fiscal Year: 2013
    ..Epidermal growth factor receptor (EGFR) tyrosine kinase, of the many factors involved in cell growth and migration has been shown to be critical in the ..
  30. COMBINATORIAL-DESIGNED NANO-PLATFORMS TO OVERCOME TUMOR DRUG RESISTANCE
    Zhenfeng Duan; Fiscal Year: 2013
    ..macrostructures with fatty acids, thiol groups, poly(ethylene glycol) (PEG), and epidermal growth factor receptor (EGFR)- targeting peptide for combinatorial self-assembly in aqueous media into nanostructures that can encapsulate siRNA ..
  31. Inhibiting EGFR and ER pathways in NSCLC
    Edward B Garon; Fiscal Year: 2013
    ..of the role of the estrogen receptor (ER) pathway in combination with the epidermal growth factor receptor (EGFR) pathway in non-small cell lung cancer (NSCLC)...
  32. GPCR Signaling &Vascular Wall Remodeling
    Gadiparthi N Rao; Fiscal Year: 2013
    ..the capacity to transactivate receptor tyrosine kinases (RTKs), among which epidermal growth factor receptor (EGFR) gained more attention...
  33. EGF RECEPTOR MEDIATED SIGNALING IN DROSOPHILA
    GERTRUD M SCHUPBACH; Fiscal Year: 2013
    ..This research project investigates the mechanisms that activate the Drosophila Epidermal Growth Factor receptor (Egfr) during oogenesis, and the cellular pathways that mediate the response to this receptor tyrosine kinase in the ..
  34. In vivo imaging of encapsulated stem cells in mouse models of tumor resection
    Khalid A Shah; Fiscal Year: 2013
    ..This will have a major impact in saving the lives of many brain cancer patients. ..
  35. MOLECULAR REGULATION OF CORNEAL WOUND HEALING
    Fu Shin X Yu; Fiscal Year: 2013
    ..The studies in the current grant period demonstrated that epidermal growth factor receptor (EGFR) is the key receptor tyrosine kinase activated upon wounding, and the wound-induced activation of EGFR and its ..
  36. Immune activation by cetuximab in head and neck cancer patients
    Robert L Ferris; Fiscal Year: 2013
    ..DESCRIPTION (provided by applicant): There is convincing clinical evidence that the epidermal growth factor receptor (EGFR)-specific monoclonal antibody (mAb), cetuximab, is effective therapy only for a subset of advanced head and neck ..
  37. CYTOSKELETAL REGULATION OF VESICLE TRANSPORT IN LIVER
    MARK A MC NIVEN; Fiscal Year: 2013
    ..These include the transferrin receptors (TfRs), the epidermal growth factor receptor (EGFR), and lysosomal hydrolases used in their degradation...
  38. Polymorphism and mutation spectrum in minorities with non-small cell lung cancer
    David P Carbone; Fiscal Year: 2010
    ..For example, the epidermal growth factor receptor (EGFR) signaling pathway is important in the development, progression, and invasion of non-small cell lung cancer...
  39. Gene therapy in the cornea
    RAJIV RAVINDRA MOHAN; Fiscal Year: 2012
    ..found decorin in the cornea interacts with transforming growth factor ? (TGF??), epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF)...
  40. Molecular Analysis of NeoAdjuvant Platinum in Triple Negative Breast Cancer
    MARK DANIEL contact PEGRAM; Fiscal Year: 2010
    ..copy number variation associated with pathologic (pCR) and clinical complete response (cCR), in patients with TNBC treated with neoadjuvant platinum-based chemotherapy, in order to identify robust biomarkers for response prediction ..
  41. Brain tumors with regulatory T-cells treated with EGFRvIII-specific T-cells
    John H Sampson; Fiscal Year: 2013
    ....
  42. Biomarkers to Guide Treatment and Improve Survival in Oral/Oropharyngeal Cancer
    Thomas E Carey; Fiscal Year: 2012
    ..virus type and copy number, p53 status and expression, BCLXL expression, the epidermal growth factor receptor (EGFR), and p16...
  43. Gene Targeted Therapy of Brain Tumors
    John H Sampson; Fiscal Year: 2010
    ..and the other identifying a significant association between clinical response to epidermal growth factor receptor (EGFR) inhibitors in patients and tumors that co-express PTEN and EGFRvIII...
  44. EGFRvIII in Pancreatic Cancer
    Maneesh Jain; Fiscal Year: 2010
    ..Overexpression of EGFR in PC cells plays a crucial role in the uncontrolled proliferation of neoplastic cells...
  45. Modifiable lifestyle-related factors and triple negative breast cancer prognosis
    SARAH JEAN NECHUTA; Fiscal Year: 2013
    ..Further, the proposed project will help sustain collaborative research efforts to promote future pooled analyses in the ABCPP. ..
  46. Development of mutant selective EGFR kinase inhibitors against EGFR T790M
    John Chant; Fiscal Year: 2010
    ..Recently, Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, have demonstrated clinical activity in ..
  47. Genetic and Molecular Mechanisms of Ethanol-Induced Developmental Defects
    RACHAEL LOUISE FRENCH; Fiscal Year: 2013
    ..are due to ethanol's effects on insulin signaling, as well as effects on the epidermal growth factor receptor (EgfR) pathway...
  48. Trafficking of the EGF receptor to the nucleus: Mechanisms and Effects
    Michael H Nathanson; Fiscal Year: 2013
    ..Specifically, the hypothesis of this FIRCA application is that the Epidermal Growth Factor receptor (EGFR), like c-met, regulates cell growth by inducing InsP3-mediated Ca2+ signals within the nucleus, and that this ..
  49. Inflammation in the pathogenesis of lung cancer
    Steven M Dubinett; Fiscal Year: 2013
    ..In fact, targeted therapy with an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) has been shown to prolong survival in advanced non-small cell lung cancer (NSCLC)...
  50. Targeted Therapy of Triple Negative Breast Cancer Using Theranostic Nanoparticles
    Lily Yang; Fiscal Year: 2013
    ..First, urokinase plasminogen activator receptor (uPAR) and epidermal growth factor receptor (EGFR) will be validated as molecular targets for targeted therapeutics using two large cohorts (>3000 cases) of ..
  51. Role of PUMA in EGFR targeted therapy in HNSCC
    Jian Yu; Fiscal Year: 2012
    ..More than 80% of HNSCC express high levels of epidermal growth factor receptor (EGFR), which correlate with poor prognosis...
  52. Mutant Epidermal Growth Factor Receptor Signaling in Lung Cancer
    Udayan Guha; Fiscal Year: 2010
    ..Mutations in the epidermal growth factor receptor (EGFR) gene have been associated with sensitivity of lung cancer patients to tyrosine kinase inhibitors (TKIs), such as ..
  53. Role of EGFR signaling in bone formation and the anabolic actions of PTH
    Ling Qin; Fiscal Year: 2013
    ..PTH strongly stimulates the expression of amphiregulin, an epidermal growth factor receptor (EGFR) ligand, in osteoblasts and osteocytes...
  54. Single Cell Analysis of EGFR Activity in Human Airway Cells Exposed to Pollutants
    RYAN MATTHEW PHILLIPS; Fiscal Year: 2013
    ..The epidermal growth factor receptor (EGFR) is a cell surface protein that helps regulate cell growth and response to external stimuli, including the ..
  55. Role of Reishi on cell surface proteins and signaling modulation in IBC
    IVETTE SUAREZ; Fiscal Year: 2013
    ..to be fully elucidated, IBC cell lines and human tissues, overexpress E-cadherin, Epidermal Growth Factor Receptor (EGFR), and Human Epidermal Growth Factor 2 (HER2) which are cell surface proteins associated with maintaining tumor ..
  56. The central role of c-Met in H. pylori pathogenesis.
    Sarah E Keates; Fiscal Year: 2010
    ..of ADAM-17 can mediate shedding of heparin-binding epidermal growth factor (HB-EGF) which in turn culminates in EGFR transactivation...
  57. Cadherin-catenin Mediated Contact Inhibition of Cell Growth
    Barry M Gumbiner; Fiscal Year: 2013
    ..mediate adhesion, Hippo pathway signaling, SFK signaling, and Epidermal Growth Factor Receptor (EGFR) signaling...
  58. Understanding and Eliminating Oncogenic EGFR Signaling in Malignant Glioma
    Alain Charest; Fiscal Year: 2013
    ..provided by applicant): For decades, we have known that overexpression of the epidermal growth factor receptor (EGFR) is a major component of the etiology of glioblastoma multiforme (GBM), yet little is known regarding the signaling ..
  59. SPORE in Pancreatic Cancer
    James Abbruzzese; Fiscal Year: 2009
    ..amp;Therapy explores the biochemical effects and biologic consequences of a series of strategies to inhibit the EGFR - Akt - NFKappaB signaling pathway. Each approach tested has potential clinical relevance to pancreatic cancer...
  60. CAML in T cell Development and Function
    Richard J Bram; Fiscal Year: 2011
    ..an essential role for CAML in mediating the proliferative effects of the Epidermal Growth Factor Receptor (EGFR), and identified a direct interaction between CAML and the kinase domain of EGF-activated EGFR...
  61. Role of EGFR in DNA Repair and Radiation Response in Non Small Cell Lung Cancer
    CHAITANYA SURESH NIRODI; Fiscal Year: 2012
    ..among these NSCLCs is that they all harbor somatic, activating mutations in the tyrosine kinase domain (TKD) of the EGFR, that have also been linked to tumor sensitivity to small molecule tyrosine kinase inhibitors, gefitinib and ..
  62. siRNA-gold nanoparticle mediated ganglioside depletion for diabetic wound healing
    AMY SUSAN PALLER; Fiscal Year: 2013
    ..receptor (IR), insulin-like growth factor-1 receptor-integrin (IGF- 1R), and epidermal growth factor receptor (EGFR) activation, all of which impact KC wound healing...
  63. Molecular Mechanisms of EGF Signaling &Iressa/Tarceva Inhibition in NSCLC
    Karen S Anderson; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): The epidermal growth factor receptor (EGFR) tyrosine kinase pathway has been demonstrated to be a key molecular target for cancer therapeutics including TKIs such as Iressa (gefinitib) and Tarceva (..
  64. GI PEPTIDE SIGNALING THROUGH TYROSINE PHOSPHORYLATION
    JUAN ENRIQUE ROZENGURT; Fiscal Year: 2010
    ..GPCR stimulation also induces rapid epidermal growth factor receptor (EGFR) transactivation...
  65. Studies of a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)
    Ravi Salgia; Fiscal Year: 2011
    ..Conduct an anti-c-Met phase I/I I clinical trial against NSCLC. Through the achievement of the goals proposed in these specific aims, we will arrive at novel therapy against c- Met in lung cancer. ..
  66. Modulation of EGFR Signaling to Promote Corneal Epithelial Wound Healing
    Brian P Ceresa; Fiscal Year: 2013
    ..Activation of the epidermal growth factor receptor (EGFR) is necessary and sufficient for the homeostasis and repair of the corneal epithelium...
  67. CHEMOPREVENTION WITH GREEN TEA POLYPHENON E (PPE) AND EGFR-TKIs IN HEAD AND NECK
    DONG MOON SHIN; Fiscal Year: 2011
    ..and erlotinib (Tarceva or OSI-774), a tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR), to prevent advanced premalignant lesions of the head and neck...
  68. Mechanistic Studies of EGFR/ErbB Receptor Tyrosine Kinases
    Daniel J Leahy; Fiscal Year: 2013
    ..receptor (EGFR/ErbB) family of receptor tyrosine kinases includes four family members in humans: EGFR (HER1, ErbB1), HER2 (ErbB2, Neu), HER3 (ErbB3), and HER4 (ErbB4)...
  69. ADAM17 in pancreatic cancer and pancreatitis
    Howard C Crawford; Fiscal Year: 2013
    ..In Aim 2, we will use genetic ablation and pharmacological inhibition of the epidermal growth factor receptor (EGFR) and its family member ERRBB3 to test if EGFR ligands released by ADAM17 are responsible for its effects on CP and ..
  70. SIGNALING BY NEUREGULINS AND ERBB4 IN BREAST CANCER
    David F Stern; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): The four members of the epidermal growth factor receptor (ErbB) family of hormone receptors are forefront targets for the new generation of FDA-approved rational cancer therapeutics, including ..
  71. FLOW EFFECTS ON ENDOTHELIAL/TROPHOBLAST INTERACTION
    Gordon C Douglas; Fiscal Year: 2013
    ..FSS induces phosphorylation of trophoblast MUC1 and co-localization of MUC1 and epidermal growth factor receptor (ErbB1) (3) FSS-mediated upregulation of [unreadable]1 integrin involves estrogen receptors (ERs), and (4) FSS causes ..
  72. Nongenomic Androgen Signaling in Sertolli Cells
    William H Walker; Fiscal Year: 2010
    ..This study will determine mechanisms by which testosterone supports spermatogenesis and identify new drug targets that may be used to regulate male fertility. ..
  73. Cellular Determinants of Apoptosis in Virus-Infected Cells
    Ganes C Sen; Fiscal Year: 2013
    ..Finally, genetically modified mice, including new IRF-3 mutant knock-in mice which have been generated for this project, will be used to assess the in vivo contribution of RIPA in controlling viral pathogenesis. ..
  74. CB1 Receptor-Mediated Tyrosine Phosphorylation of FAK and ERK in Neurons
    George D Dalton; Fiscal Year: 2012
    ....
  75. Hyaluronan in Epidermal Injury Responses
    Edward Maytin; Fiscal Year: 2009
    ..the mechanism of increased HA requires the release of HB-EGF, activation of the epidermal growth factor receptor (EGFR) pathway, and activation of the Has enzymes which synthesize HA...
  76. The Molecular Basis for Erlotinib-Resistance in Lung Cancer with wild-type EGFR
    NEAL GILPIN SATTERLY; Fiscal Year: 2010
    ..10% of non-small cell lung cancers (NSCLC) in the United States, mutations in the epidermal growth factor receptor (EGFR) are present that drive cancer proliferation and survival...
  77. Mechanisms of Glioma Resistance to EGFR Inhibition
    JILL E WYKOSKY; Fiscal Year: 2012
    ..confers aggressive tumor growth and poor prognosis is deletional mutation of the epidermal growth factor receptor (EGFR) resulting in a constitutively active, oncogenic form of the protein (EGFR*)...
  78. Biomolecular Analysis using Liquid Crystals
    Nicholas L Abbott; Fiscal Year: 2013
    ..The work is focused on epidermal growth factor receptor (EGFR), given that its overexpression and mutation has been closely-associated with some of the most incurable cancers...
  79. TOPOISOMERASE I INHIBITORS IN LEUKEMIA AND SOLID TUMORS
    Scott H Kaufmann; Fiscal Year: 2010
    ..Collectively, these studies are designed to provide new insight into the mechanism of action of topo I poisons, and identify strategies for enhancing their efficacy. ..
  80. Direct identification of ready-to-use peptoid-DOTA theranostic systems
    DAMITH GOMIKA UDUGAMASOORIYA; Fiscal Year: 2013
    ..This library will be screened against Epidermal Growth Factor Receptor (EGFR) and ephrin receptor A2 (EphA2) as model target systems that overexpress in many cancer types which ideally form ..
  81. IN VIVO CEREBRAL OXIDATIVE METABOLISM IN HYPOXIC NEWBORNS
    MARIA D DELIVORIA PAPADOPOULOS; Fiscal Year: 2010
    ..phosphorylation of CaM kinase IV by the tyrosine kinases, Src tyrosine kinase and epidermal growth factor receptor (EGFR) tyrosine kinase...
  82. Detection of NSCLC-derived mutant RNA in platelets
    Bakhos A Tannous; Fiscal Year: 2013
    ..example of this approach has been the development of therapies targeting the epidermal growth factor receptor (EGFR) in NSCLC...
  83. Protein Biosensors with Customized Properties for Live-Cell Imaging
    Balaji M Rao; Fiscal Year: 2013
    ..by characterizing thei translocation in cells expressing wild-type or mutant Epidermal Growth Factor Receptor (EGFR) (Aim 2)...
  84. Quantification of Tyrosine Phosphorylation and Kinase Expression in NSCLC
    John M Koomen; Fiscal Year: 2013
    ..As an example, patients with driver mutations in the epidermal growth factor receptor (EGFR) can be treated with Erlotinib or other targeted EGFR inhibitors to improve their outcomes...
  85. MR SIGNAL AMPLIFICATION FOR RECEPTOR IMAGING
    Alexei A Bogdanov; Fiscal Year: 2013
    ..Human epidermal growth factor receptor (EGFR) is overexpressed in 15-20% of all breast carcinomas and its expression level correlates with the ability of breast ..
  86. Roles of EGFR and miR-143/miR-145 in Western diet-promoted colonic tumorigenesis
    BRUCE MARC BISSONNETTE; Fiscal Year: 2013
    ..We showed that Western diet up-regulated ligands for epidermal growth factor receptors (EGFR). Furthermore, EGFR was required for tumor promotion...
  87. Dual Oxidase in Airway Epithelial Injury and Inflammation
    Albert van Der Vliet; Fiscal Year: 2013
    ..oxidative mechanisms by which DUOX1 activation promotes the activation of epidermal growth factor receptor (EGFR) as a critical event in wound responses and inflammatory mediator production, and observed increased DUOX1 ..
  88. Targeting RET in Lung Cancer
    Pasi A Janne; Fiscal Year: 2013
    ..Compelling clinical examples include somatic mutations in the epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC), BRAF mutations in melanoma, and BCR-ABL translocations in chronic myeloid ..
  89. Regulation of EGFR Signaling by the Endocytic Pathway
    Brian P Ceresa; Fiscal Year: 2013
    ..this process, we are using the prototypical receptor tyrosine kinase, the epidermal growth factor receptor (EGFR), as a model...
  90. Quantitative Biomarker Imaging for Early Therapy Response Assessment in Cancer
    James M Mountz; Fiscal Year: 2013
    ..squamous cell carcinoma of head and neck using novel targeted agents against epidermal growth factor receptor (EGFR) and angiogenesis, including vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR)...
  91. Genomic and Proteomic Biomarkers for Head and Neck Cancer Risk and Prognosis
    Ann Marie Egloff; Fiscal Year: 2013
    ..Epidermal growth factor receptor (EGFR) and gastrin-releasing peptide receptor (GRPR) are strongly implicated In HNSCC development/progression. Dr...
  92. Integrating cellular and molecular heterogeneity of TKI response in NSCLC cells
    PETER LEE FRICK; Fiscal Year: 2013
    ..provided by applicant): Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)-activating mutations respond well to EGFR-targeted tyrosine kinase inhibitors (TKIs)...
  93. Genotypic Interactions in Brain Cancer Heterogeneity
    Frank B Furnari; Fiscal Year: 2013
    ..The most common of these alterations, ?EGFR, (also known as de2-7EGFR, deltaEGFR and EGFR*) results in a constitutively active mutant receptor with tumor ..
  94. Elucidating the Fas-activated inflammation-signaling complex (FISC)
    Mihail Iordanov; Fiscal Year: 2013
    ..the stress-activated protein kinases (SAPK) JNK and p38 MAP kinase, and the epidermal growth factor receptor (EGFR)-Ras-ERK MAP kinase cascade...
  95. CT Volume Measurement of Lung Cancer treated with Erlotinib: Genomic Correlation
    Mizuki Nishino; Fiscal Year: 2013
    ..cancer treatment was the discovery of the somatic activating mutations of the epidermal growth factor receptor (EGFR) tyrosine kinase domain in non-small cell lung cancer (NSCLC), which is associated with a dramatic clinical ..
  96. Genetic Modifiers such as Fas Regulate Tumor-Cell Dependence on Mutant EGFR
    Trever G Bivona; Fiscal Year: 2013
    ..We have focused on human lung cancers that harbor activating mutations in the epidermal growth factor receptor (EGFR)...
  97. A Small Molecule to Activate Cetuximab to Kill K-RAS Mutant Colorectal Tumors
    Barry Jones; Fiscal Year: 2013
    ..The antibodies were selected for their ability to kill tumors by blockade of the epidermal growth factor receptor (EGFR)...
  98. Head and Neck squamous cell carcinoma radiation response modulation by HPV
    Randall J Kimple; Fiscal Year: 2013
    ..traditional HNSCC to radiation and chemotherapy and to examine the ability of epidermal growth factor receptor (EGFR) inhibitors to sensitize HPV-associated head and neck cancer to radiation despite low levels of EGFR expression...
  99. ErbB Family in Pituitary Tumors
    Odelia Cooper; Fiscal Year: 2013
    ..invasive tumors using immunohistochemistry techniques, fluorescent in situ hybridization, and assays for serum EGFR and erbB2...
  100. Targeting SMURF2 as a novel therapy for EGFR driven tumors
    Dipankar Ray; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Over-expression of epidermal growth factor receptor (EGFR) drives several cancers including lung, head &neck (H&N) and colorectal, where targeting EGFR kinase activity has produced definite ..
  101. Targeting Sterol Gene SC4MOL and EGFR as Synergistic Anti-Cancer Strategy
    Igor Astsaturov; Fiscal Year: 2013
    Abstract Epidermal growth factor receptor (EGFR) has been heavily exploited as a target for blockade in cancer therapy...